Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

ClinicalTrials.gov ID: NCT01711814

Public ClinicalTrials.gov record NCT01711814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 6:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label, Noncomparative, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the long-term safety and efficacy of ASP015K in subjects with Rheumatoid Arthritis (RA) who have completed a preceding Phase 2 ASP015K RA study.

Study identification

NCT ID
NCT01711814
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
611 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 25, 2012
Primary completion
Mar 24, 2016
Completion
Mar 24, 2016
Last update posted
Oct 20, 2024

2012 – 2016

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
Site US3218 Birmingham Alabama 35216
Site US828 La Jolla California 92093-0943
Site US3227 Palm Desert California 92260
Site US219 Palo Alto California 94304
Site US3332 Santa Maria California 93454
Site US3331 Colorado Springs Colorado 80920
Site US1894 Jacksonville Florida 32216
Site US3232 Orlando Florida 32804
Site US702 Morton Grove Illinois 60053
Site US3226 Vernon Hills Illinois 60061
Site US3329 Elizabethtown Kentucky 42701
Site US291 Wheaton Maryland 20902
Site US3298 Hickory North Carolina 28602
Site US3300 Oklahoma City Oklahoma 73103
Site US345 Duncansville Pennsylvania 16635
Site US3304 Wyomissing Pennsylvania 19610
Site US3306 Knoxville Tennessee 37909
Site US3319 Austin Texas 78705
Site US3327 Chesapeake Virginia 23320
Site US3320 Clarksburg West Virginia 26301

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01711814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2024 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01711814 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →